Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel

Inclusion Criteria:

* Written informed consent (+ optional for TR) must be given according to ICH/GCP and national/local regulations.
* Patient is at least 18 years of age .
* Unresectable locally advanced or metastatic pancreatic cancer.
* Histologically or cytologically confirmed adenocarcinoma of the pancreas. Islet cell neoplasms are excluded.
* Evaluable or measurable disease, not in a previously irradiated area.
* Life expectancy of at least 12 weeks.
* WHO ECOG performance status ≤ 2
* Adequate organ function.
* Adequate bone marrow, hepatic and renal function. Acceptable coagulation (prothrombin time and partial thromboplastin time within +/- 15% of normal limits).
* No clinically significant abnormalities in urinalysis.
* Effective contraception for both male and female patients if applicable. Women of childbearing potential must have negative blood pregnancy test at screening visit.

Exclusion criteria:

* Prior chemotherapy, radiotherapy, surgery or other investigational therapy for the treatment for metastatic disease. Adjuvant treatment with gemcitabine or 5-FU is allowed provided at least 6 months have elapsed since completion of the last dose.
* Major surgery within 4 weeks of the start of the study.
* Irradiation within 3 weeks prior to study entry.
* Brain metastasis (known or suspected).
* Serious medical risk factors involving any of the major organ systems, including high cardiovascular risk including coronary stenting or myocardial infarction in the last year and psychiatric disorders.
* Historical or active infection with HIV, hepatitis B or C.
* History of connective tissue disorders (eg. lupus, scleroderma, arteritis nodosa, etc).
* History of interstitial lung disease.
* History of peripheral artery disease.
* Previous (within 5 years) or concurrent malignancies at other sites with the exception of surgically cured or adequately treated carcinoma in-situ of the cervix and basal cell carcinoma of the skin.
* Known allergy or any other adverse reaction to any of the drugs or to any related compound.
* Use of Coumadin.
* Organ allografts requiring immunosuppressive therapy.
* Pregnancy or breast-feeding.
* Medical, social or psychological condition which, in the opinion of the investigator, would not permit the patient to complete the study or sign meaningful informed consent.